Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN

Braidwell LP trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 16.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,730,481 shares of the company’s stock after selling 542,868 shares during the quarter. Braidwell LP owned 1.91% of Dyne Therapeutics worth $34,541,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Chung Wu Investment Group LLC bought a new position in shares of Dyne Therapeutics in the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after buying an additional 955 shares during the period. Arkadios Wealth Advisors purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at about $128,000. Finally, Tower Research Capital LLC TRC grew its stake in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Insider Activity at Dyne Therapeutics

In related news, Director Brian S. Posner purchased 3,000 shares of Dyne Therapeutics stock in a transaction dated Friday, March 6th. The stock was purchased at an average cost of $15.06 per share, with a total value of $45,180.00. Following the transaction, the director owned 11,500 shares in the company, valued at approximately $173,190. The trade was a 35.29% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DYN shares. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price objective on shares of Dyne Therapeutics in a research note on Monday, December 8th. Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a research report on Monday, December 8th. Tudor Pickering set a $23.00 target price on Dyne Therapeutics in a report on Tuesday, December 9th. Finally, Evercore dropped their price target on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $17.92 on Friday. The company has a market cap of $2.96 billion, a PE ratio of -5.06 and a beta of 1.34. The firm’s 50 day moving average price is $16.99 and its 200-day moving average price is $17.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.